Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Total Current Liabilities (2016 - 2025)

Macrogenics (MGNX) has disclosed Total Current Liabilities for 14 consecutive years, with $43.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 22.36% to $43.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.1 million, a 22.36% decrease, with the full-year FY2025 number at $43.1 million, down 22.36% from a year prior.
  • Total Current Liabilities was $43.1 million for Q4 2025 at Macrogenics, down from $44.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $74.6 million in Q4 2021 to a low of $39.0 million in Q2 2025.
  • A 5-year average of $54.6 million and a median of $54.2 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 52.36% in 2021, then tumbled 34.82% in 2022.
  • Macrogenics' Total Current Liabilities stood at $74.6 million in 2021, then crashed by 34.82% to $48.6 million in 2022, then rose by 15.42% to $56.1 million in 2023, then dropped by 1.03% to $55.5 million in 2024, then decreased by 22.36% to $43.1 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Total Current Liabilities are $43.1 million (Q4 2025), $44.5 million (Q3 2025), and $39.0 million (Q2 2025).